TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GeoVax Labs ( (GOVX) ) has provided an announcement.
GeoVax Labs held a special meeting of stockholders on November 26, 2025, where they approved two significant proposals. The stockholders approved the issuance of up to 11,904,768 shares of common stock upon exercise of warrants issued in a private placement offering and an amendment for a reverse stock split at a ratio determined by the Board of Directors.
The most recent analyst rating on (GOVX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
Average Trading Volume: 785,587
Technical Sentiment Signal: Sell
Current Market Cap: $11.27M
For detailed information about GOVX stock, go to TipRanks’ Stock Analysis page.